Navigation Links
Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
Date:12/23/2009

SAN DIEGO, Dec. 23 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that on December 23, 2009 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 64,000 shares of common stock to two new employees.

Both of the stock options are intended to be incentive stock options to the extent permitted by law and both have an exercise price per share equal to $8.45, the fair market value on the grant date. Each stock option vests over the course of four years, with 25% vesting on the one-year anniversary of the grant date and 1/48 of the shares vesting monthly thereafter so that all of the shares subject to the stock option shall be vested on the fourth anniversary of the grant date, subject to the new employee's continued service relationship with the Company on each such date. Each stock option has a ten year term and is subject to the terms and conditions of the Company's 2007 Equity Incentive Award Plan and the stock option agreement pursuant to which the option is granted.

Both stock options were granted as an inducement material to the new employees' entering into employment with Orexigen Therapeutics in accordance with NASDAQ Listing Rule 5635(c)(4).

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave®, has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic(TM), has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
3. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
4. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
7. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
8. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
9. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
10. PTC Therapeutics Closes $50 Million Financing
11. Fate Therapeutics iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... February 15, 2012 It has become common ... to be required to submit to random drug screens as ... this billable procedure is to prevent and reduce opioid associated ... the efficacy of drug testing people with chronic pain.   ...
... N.J., Feb. 15, 2012  Omthera Pharmaceuticals, Inc., a ... Jerry Wisler, President and Chief Executive Officer, will present ... Thursday, February 16, 2012 at 3:20 p.m. EST.  He ... on February 29, 2012 at 11:00 a.m. EST.  Both ...
Cached Medicine Technology:New Evidence Points to a "Profits Over Efficacy" Approach to Drug Testing 2Omthera Pharmaceuticals, Inc. to Present at Leerink Swann 2012 Global Healthcare Conference and Citi 2012 Global Healthcare Conference 2
(Date:4/18/2014)... What,s one of your worst memories? How did it ... felt during a negative personal experience, such as how ... lead to emotional distress, especially when you can,t stop ... creep up, thinking about the context of the memories, ... and effective way to alleviate the negative effects of ...
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... scientists at SUNY Downstate Medical Center in Brooklyn and ... patent for their virtual telemicroscope. This patented software permits ... patients living in remote locations around the world. ... pathology at SUNY Downstate, and Jiang Gu, MD, PhD, ...
... on investigations, -- Three-fifths want high school ... stats and awards from guilty pro,athletes, FAIRFIELD, ... Baseball season-opener approaches, a new national poll,indicates that ... use among,professional athletes., On average, Americans polled ...
... DIEGO, March 27 Gen-Probe Incorporated,(Nasdaq: GPRO ) ... Leerink,Swann "Bugs and Drugs: The Future of Molecular Diagnostics ... approximately 1:20 p.m. Eastern,Time. The presentation is scheduled to ... on the investor information section of Gen-Probe,s website,at ...
... physical disability does, study shows , , THURSDAY, March 27 (HealthDay ... almost as often as physical disability does, Australian researchers report. ... 55, who had paying jobs before a stroke found that ... about the same ratio as in a recent U.S. study, ...
... 27 The Anthem Blue Cross and Blue Shield,Foundation announced ... San Luis,Valley Chapter of the American Red Cross to assist ... bottles, formula and water,and to aid volunteers who are distributing ... been affected by the recent Salmonella water,contamination., "One of ...
... dairy cow is back at her Kansas farm ... surgery performed at Kansas State University,s,Veterinary Medical Teaching ... the veterinary students assigned to,her case, sustained a ... in her right knee ruptured. Dr. David Anderson, ...
Cached Medicine News:Health News:SUNY researcher issued patent for virtual telemicroscope 2Health News:Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs 2Health News:Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs 3Health News:Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference 2Health News:Depression After Stroke Can Be Debilitating 2Health News:Anthem Blue Cross and Blue Shield Foundation Donates $7,500 to San Luis Valley American Red Cross to Assist Residents Affected by Water Contamination Crisis 2Health News:'Wildcat Power Cord' Repairs Cruciate Ligament in Dairy Cow's Knee 2Health News:'Wildcat Power Cord' Repairs Cruciate Ligament in Dairy Cow's Knee 3
... system builds on the basic infrastructure ... in the system are networked to ... Windows® operating system, which monitors system ... personal computer, RoamAlert Integrity provides reporting ...
... Awarix provides an enterprise visibility ... throughput, improve caregiver effectiveness, and increase ... edge RFID location systems and geospatial ... systems to create a real time ...
MONOJECT MAGELLAN Safety Blood Collection Needle...
This is adapted to microplate or card....
Medicine Products: